Evidence map›Paper›PMID 36875914›Full record

ArticleJACC. CardioOncology2023

Cardio-Oncology Guidelines and Strength of the Evidence.

Haoyi Zheng, Huichun Zhan

Abstract readEditorial
In one paragraph

Article in JACC. CardioOncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Research Priorities and Future Directions in Cardio-Oncology.Current treatment options in oncology · 2026
    Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Haoyi ZhengCardio-Oncology Program, The Heart Center, Saint Francis Hospital, Roslyn, New York, USA.
Huichun ZhanDepartment of Medicine, Stony Brook School of Medicine, Stony Brook, New York, USA.

Funding

Cell Competition in Myeloproliferative NeoplasmsR01CA266294 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI Huichun Zhan · 2022 to 2026
$1.8M
Identification of Therapeutic Targets in the Hematopoietic Vascular NicheI01BX003947 · VA · NORTHPORT VA MEDICAL CENTER · PI ZHAN, HUICHUN · 2020 to 2023
–
BLRD VA I01 BX003947NCI NIH HHS R01 CA266294
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cardio-oncologyevidenceguidelinesrecommendations

Identifiers

PMID36875914
PMCPMC9982203

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.